Intrexon Appoints Executives to Expand European and Asian Markets, Accelerate
Technology Platform Development
GERMANTOWN, Md., Nov. 18, 2013
GERMANTOWN, Md., Nov. 18, 2013 /PRNewswire/ --Intrexon Corporation (NYSE:
XON), a leader in synthetic biology, today announced the appointments of Vice
President, Business Development for Europe and Asia Peter Seufer-Wasserthal,
Ph.D., and Chief Information Officer Dana Di Ferdinando,
Intrexon Chief Operating Officer Krish Krishnan welcomed Ms. Di Ferdinando and
Dr. Seufer-Wasserthal: "We are excited to have Ms. Di Ferdinando and Dr.
Seufer-Wasserthal join Intrexon at this stage of our growth. Dana will lead
development of the next generation of Intrexon's proprietary technologies,
particularly UltraVector®, an industry-leading software platform that enables
our collaborators to design, test, and produce complex biological solutions
with the goal of generating superior commercial products. Peter will expand
Intrexon's presence even further into Europe and Asia, growing our
international relationships to establish additional collaborations abroad. I
am confident that their respective professional experiences and insights will
be a tremendous asset to Intrexon."
Dr. Seufer-Wasserthal will broaden Intrexon's European and Asian market
sectors in Food, Health, Energy and Environment, establishing Exclusive
Channel Collaborations and other research and development opportunities.
Prior to joining Intrexon, Dr. Seufer-Wasserthal was Senior Vice President of
Pharmaceuticals at Codexis, Inc., where he was responsible for closing
numerous licensing, research and supply agreements, and adapting IP strategy
to increase account penetration. Before Codexis, Inc., Dr. Seufer-Wasserthal
managed drug discovery collaborations, licensed pre-clinical candidates and
purchased services for drug development projects as Senior Vice President of
Clinical Development at Morphochem AG. He holds a Ph.D. in organic chemistry
from the Technical University of Graz.
Ms. Di Ferdinando brings to Intrexon more than 25 years of professional
experience in the management, engineering, analysis and implementation of
integrated solutions for life sciences and technology companies. Most
recently, she was CIO at Arena Pharmaceuticals, where she managed IT functions
and oversaw enterprise business technology initiatives and application
development efforts at Arena's U.S., European and Asian locations. Prior to
Arena, Ms. Di Ferdinando worked for major consulting and analytics companies
Deloitte & Touche and Science Applications International Corporation (SAIC).
Ms. Di Ferdinando holds a B.S. in Computer Science from Rutgers University and
an M.S. in Operations Research from Stanford University.
About Intrexon Corporation
Intrexon Corporation (NYSE: XON) is a leader in synthetic biology focused on
collaborating with companies in Health, Food, Energy and the Environment to
create biologically-based products that improve the quality of life and the
health of the planet. Through the company's proprietary UltraVector®
platform, Intrexon provides its partners with industrial-scale design and
development of complex biological systems. The UltraVector® platform delivers
unprecedented control over the quality, function, and performance of living
cells. We call our synthetic biology approach and integrated technologies
Better DNA®, and we invite you to discover more at www.dna.com.
Intrexon, UltraVector, RheoSwitch Therapeutic System, RTS and Better DNA are
trademarks of Intrexon and/or its affiliates. Other names may be trademarks
of their respective owners.
Intrexon Corporation Contact:
Vice President, Corporate Communications
Tel: +1 323-842-7779
SOURCE Intrexon Corporation
Press spacebar to pause and continue. Press esc to stop.